AgingResearch.NewsJoin free

Phenytoin

InterventionApproved 1953

3 papers3 findings

PubChemChEBIMeSH

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 2 independent labs in 1 country
  • 1 finding against
  • 47 trials, none about aging, 25 with no results posted
  • 6 of 47 trials sponsored by its developers
  • Animals2

Outcomes

1

Lifespan

upin mice1no changein rats1+25% mean life span

2 studies

  1. Phenytoin extends lifespan in mice (+25% mean life span).

    “The chronic treatment of female C3H/Sn mice with phenformin (2 mg/day) and diphenylhydantoin (2 mg/day) prolonged mean life span by 23 and 25%, respectively”

    Animals2 mg/dayfemales

    Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice

    Gerontology1 Jan 1980

  2. Phenytoin has no effect on lifespan in rats.

    “The administration of diphenylhydantoin (7.5 mg/day per rat) would not change these parameters.”

    Animals7.5 mg/day per ratfemales

    Effect of buformin and diphenylhydantoin on the life span, estrous function and spontaneous tumor incidence in rats

    Voprosy onkologii1 Jan 1980

Associations

1

Spontaneous tumour incidence

downin mice1

1 study

  1. Phenytoin lowers the risk of spontaneous tumour incidence in mice (2.3 times).

    “decreased spontaneous tumour incidence by 4.0 and 2.3 times, respectively”

    Animals2 mg/dayfemales

    Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice

    Gerontology1 Jan 1980

Trials

0 about aging, of 47

Approved

Repurposing

All 28

In trials

  • Precursor cell lymphoblastic leukemia lymphoma

    Phase 1/2Results posted1 trial

Readouts due

Stopped

Development

Companies

Trial sponsors

Latest

Related